Vanguard Group
FHTX icon

Vanguard Group’s Foghorn Therapeutics FHTX Stock Holding History

Vanguard Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.4M Buy
1,928,992
+29,535
+2% +$134K ﹤0.01% 2946
2025
Q3 		$9.29M Buy
1,899,457
+14,784
+0.8% +$78.4K ﹤0.01% 3019
2025
Q2 		$8.86M Buy
1,884,673
+50,045
+3% +$209K ﹤0.01% 2966
2025
Q1 		$6.7M Buy
1,834,628
+84,968
+5% +$387K ﹤0.01% 3060
2024
Q4 		$8.26M Buy
1,749,660
+17,681
+1% +$129K ﹤0.01% 3055
2024
Q3 		$16.1M Buy
1,731,979
+672,494
+63% +$4.87M ﹤0.01% 2706
2024
Q2 		$6.09M Sell
1,059,485
-43,008
-4% -$256K ﹤0.01% 3166
2024
Q1 		$7.4M Buy
1,102,493
+77,380
+8% +$430K ﹤0.01% 3126
2023
Q4 		$6.61M Buy
1,025,113
+6,434
+0.6% +$27.8K ﹤0.01% 3175
2023
Q3 		$5.09M Buy
1,018,679
+3,742
+0.4% +$28.8K ﹤0.01% 3240
2023
Q2 		$7.15M Sell
1,014,937
-7,028
-0.7% -$49.1K ﹤0.01% 3135
2023
Q1 		$6.34M Buy
1,021,965
+4,077
+0.4% +$26.7K ﹤0.01% 3195
2022
Q4 		$6.49M Buy
1,017,888
+4,966
+0.5% +$37.4K ﹤0.01% 3168
2022
Q3 		$8.69M Buy
1,012,922
+5,333
+0.5% +$68.6K ﹤0.01% 3018
2022
Q2 		$13.7M Buy
1,007,589
+146,819
+17% +$1.89M ﹤0.01% 2824
2022
Q1 		$13.1M Buy
860,770
+16,079
+2% +$221K ﹤0.01% 3008
2021
Q4 		$19.3M Buy
844,691
+4,774
+0.6% +$68.6K ﹤0.01% 2858
2021
Q3 		$11.7M Buy
839,917
+156,139
+23% +$1.73M ﹤0.01% 3149
2021
Q2 		$7.3M Buy
683,778
+276,444
+68% +$3.01M ﹤0.01% 3376
2021
Q1 		$5.37M Buy
407,334
+3,883
+1% +$63.6K ﹤0.01% 3495
2020
Q4 		$8.18M Buy
+403,451
New +$7.73M ﹤0.01% 3097

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's FHTX Position: Q4 2025 in Review

Vanguard Group increased its Foghorn Therapeutics (FHTX) stake by 1.6% in Q4 2025, buying an estimated $134K and bringing the position to 1,928,992 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

Vanguard Group first reported a position in FHTX in Q4 2020 and has held it in 21 quarters since. The position peaked at $19.3M in Q4 2021. 93 funds tracked by Wall St. Rank hold FHTX as of Q4 2025.

  • Vanguard Group held 1,928,992 shares of Foghorn Therapeutics worth $10.4M as of Q4 2025.
  • Vanguard Group bought 29,535 Foghorn Therapeutics shares in Q4 2025, an estimated $134K.
  • Foghorn Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2946 holding.
  • Vanguard Group first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's Foghorn Therapeutics position peaked at $19.3M in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.